Navigation Links
3SBio Announces Changes to its Board of Directors

SHENYANG, China, March 10 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced changes to its board of directors (the "Board"). Ms. Liping Xu, Executive Director and Vice President, will retire from the Board and her position as a company officer for health reasons, effective March 10, 2010. Ms. Xu was one of the founders of the company and has been a director of 3SBio and its predecessor company, Shenyang Sunshine, since 1993. Concurrently, effective March 10, 2010, Mr. Peiguo Cong will join the Board and serve as an independent, non-executive director.

Mr. Dan Lou, Chairman of the Board, said, "On behalf of the Board, I would like to thank Ms. Xu for her significant contributions as a founder, director and key executive of the company. We wish her well with her future endeavors." He continued, "We are also pleased to welcome Mr. Cong to the Board as an independent, non-executive director and look forward to his advice and counsel."

Mr. Peiguo Cong has been the managing partner of Beijing Jun You Law Firm since 1994. Mr. Cong also currently serves as a member of the Financial Securities Committee of the China National Lawyers Association, member of the All China Federation of Industry and Commerce, director of the Chinese Society of Mergers and Acquisitions, independent committee member of the Credit Committee of the National Development Bank, and part-time professor at Peking University. In addition, Mr. Cong serves as an independent director of China Southern Fund Management Company and Tianjin Lishen Battery Joint-Stock Co., Ltd. Mr. Cong obtained his bachelor's degree in law and master's degree in economic law from Peking University.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at .

Safe Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. The accuracy of these statements may be impacted by a number of business factors and uncertainties that could cause actual results to differ materially from those projected or anticipated, including factors related to: the ability of the company to avoid disruption to its business caused by changes to the Board and management; the ability of the company to recruit and retain suitable members of the Board and management; and other risks outlined in 3SBio's filings with the Securities and Exchange Commission. 3SBio does not undertake any obligation to update this forward-looking information, except as required under applicable law.

    For more information, please contact:

    Investor Contacts

    3SBio Inc.
     Bo Tan
     Chief Financial Officer
     Tel:   +86-24-2581-1820

     Tom Folinsbee
     Director of Investor Relations
     Tel:   +852-8191-6991


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial
2. 3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
3. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
4. 3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia
5. 3SBio Inc. to Report 2009 Fourth Quarter and Full Year Results on February 11, 2010
6. 3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM)
7. 3SBio Inc. Announces Unaudited Third Quarter 2009 Results
8. 3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
9. 3SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009
10. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
11. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
(Date:10/13/2015)... the United States , ... represents about 14% of all new cases of kidney cancer.   ... Canada and Europe .  PRCC represents ... --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces ... AB (publ) ("AstraZeneca") have completed enrolment in a global Phase II ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
(Date:10/12/2015)... 12, 2015 cell surface marker detection ... 2022, according to a new report by Grand View Research, ... in incidence of oncology diseases and other cell-associated disorders. ... to reach USD 6.49 billion by 2022, according to a ... demand can be attributed to rise in incidence of oncology ...
(Date:10/12/2015)... DIEGO , Oct. 12, 2015  Patara ... debilitating allergic and inflammatory diseases and conditions, today ... A preferred stock financing. Concurrent with the close ... entered into a Loan and Security Agreement with ... up to $7 million. Patara will use the ...
Breaking Biology Technology:
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
(Date:9/28/2015)... Synaptics Inc. (NASDAQ: SYNA ), the ... Lenovo has selected Synaptics , Natural ID ™ ... smartphone, the Vibe P1. The new Vibe P1 ... and provide swift access to applications and mobile payments ... FS4202 sensor solution utilizes AES256-bit encryption of the fingerprint ...
Breaking Biology News(10 mins):